Antihypertensive treatment in patients with type-2 diabetes mellitus: What guidance from recent controlled randomized trials?

Alberto Zanchetti, Luis M. Ruilope

Research output: Contribution to journalArticle

Abstract

Background: Patients with type-2 diabetes have a high prevalence of hypertension and show an elevated incidence of cardiovascular events and nephropathy. Objectives: Recent randomized trials of antihypertensive therapy providing information about cardiovascular and renal risk in diabetes, blood pressure goals and best suitable drugs were reviewed. Findings: Evidence that association of type-2 diabetes with hypertension markedly increases cardiovascular and renal risk is incontrovertible: even blood pressure values in the high-normal range represent a more relevant risk than in non-diabetics. More versus less intensive blood pressure lowering or active versus placebo treatment can significantly prevent cardiovascular and renal events, with a particularly consistent reduction of proteinuria and microalbuminuria. Although several of the trials showing significant reduction of cardiovascular or renal risk achieved diastolic blood pressure (DBP) between 75 and 82 mmHg, systolic blood pressure (SBP) <140 mmHg was never achieved in trials showing cardiovascular benefits and SBP <130 mmHg was only achieved in two trials in normotensive subjects showing proteinuria reduction. The recommendation given by all major guidelines to lower SBP <130 mmHg appears to be difficult to comply with. Evidence of the superiority or inferiority of different drug classes (angiotensin-converting enzyme inhibitors, calcium antagonists, diuretics and beta-blockers) is rather vague, especially for cardiovascular protection. As to angiotensin-receptor antagonists, losartan has shown significant cardiovascular protection over a beta-blocker, and irbesartan, although not showing cardiovascular benefits over a calcium antagonist, was significantly better in retarding renal dysfunction and failure. Conclusions: In most trials on hypertensive diabetics, the large majority of patients were on two, three and even four-drug therapy. Therefore, it appears reasonable that all effective and well tolerated antihypertensive agents can be used in association to achieve DBP <80 mmHg and, whenever possible, SBP <130 or 135 mmHg, with the regular inclusion of an angiotensin-receptor antagonist for its proven renoprotective action. Hopefully, better guidance will be provided by further trials.

Original languageEnglish
Pages (from-to)2099-2110
Number of pages12
JournalJournal of Hypertension
Volume20
Issue number11
DOIs
Publication statusPublished - Nov 2002

Fingerprint

Type 2 Diabetes Mellitus
Antihypertensive Agents
Randomized Controlled Trials
Blood Pressure
Therapeutics
Kidney
irbesartan
Angiotensin Receptor Antagonists
Proteinuria
Hypertension
Calcium
Losartan
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Pharmaceutical Preparations
Renal Insufficiency
Reference Values
Placebos
Guidelines

Keywords

  • Antihypertensive therapy
  • Cardiovascular events
  • Diabetes mellitus
  • Diabetic nephropathy

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine

Cite this

Antihypertensive treatment in patients with type-2 diabetes mellitus : What guidance from recent controlled randomized trials? / Zanchetti, Alberto; Ruilope, Luis M.

In: Journal of Hypertension, Vol. 20, No. 11, 11.2002, p. 2099-2110.

Research output: Contribution to journalArticle

@article{3eb83c4e2cd94559b57e322d9b86c512,
title = "Antihypertensive treatment in patients with type-2 diabetes mellitus: What guidance from recent controlled randomized trials?",
abstract = "Background: Patients with type-2 diabetes have a high prevalence of hypertension and show an elevated incidence of cardiovascular events and nephropathy. Objectives: Recent randomized trials of antihypertensive therapy providing information about cardiovascular and renal risk in diabetes, blood pressure goals and best suitable drugs were reviewed. Findings: Evidence that association of type-2 diabetes with hypertension markedly increases cardiovascular and renal risk is incontrovertible: even blood pressure values in the high-normal range represent a more relevant risk than in non-diabetics. More versus less intensive blood pressure lowering or active versus placebo treatment can significantly prevent cardiovascular and renal events, with a particularly consistent reduction of proteinuria and microalbuminuria. Although several of the trials showing significant reduction of cardiovascular or renal risk achieved diastolic blood pressure (DBP) between 75 and 82 mmHg, systolic blood pressure (SBP) <140 mmHg was never achieved in trials showing cardiovascular benefits and SBP <130 mmHg was only achieved in two trials in normotensive subjects showing proteinuria reduction. The recommendation given by all major guidelines to lower SBP <130 mmHg appears to be difficult to comply with. Evidence of the superiority or inferiority of different drug classes (angiotensin-converting enzyme inhibitors, calcium antagonists, diuretics and beta-blockers) is rather vague, especially for cardiovascular protection. As to angiotensin-receptor antagonists, losartan has shown significant cardiovascular protection over a beta-blocker, and irbesartan, although not showing cardiovascular benefits over a calcium antagonist, was significantly better in retarding renal dysfunction and failure. Conclusions: In most trials on hypertensive diabetics, the large majority of patients were on two, three and even four-drug therapy. Therefore, it appears reasonable that all effective and well tolerated antihypertensive agents can be used in association to achieve DBP <80 mmHg and, whenever possible, SBP <130 or 135 mmHg, with the regular inclusion of an angiotensin-receptor antagonist for its proven renoprotective action. Hopefully, better guidance will be provided by further trials.",
keywords = "Antihypertensive therapy, Cardiovascular events, Diabetes mellitus, Diabetic nephropathy",
author = "Alberto Zanchetti and Ruilope, {Luis M.}",
year = "2002",
month = "11",
doi = "10.1097/00004872-200211000-00001",
language = "English",
volume = "20",
pages = "2099--2110",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Antihypertensive treatment in patients with type-2 diabetes mellitus

T2 - What guidance from recent controlled randomized trials?

AU - Zanchetti, Alberto

AU - Ruilope, Luis M.

PY - 2002/11

Y1 - 2002/11

N2 - Background: Patients with type-2 diabetes have a high prevalence of hypertension and show an elevated incidence of cardiovascular events and nephropathy. Objectives: Recent randomized trials of antihypertensive therapy providing information about cardiovascular and renal risk in diabetes, blood pressure goals and best suitable drugs were reviewed. Findings: Evidence that association of type-2 diabetes with hypertension markedly increases cardiovascular and renal risk is incontrovertible: even blood pressure values in the high-normal range represent a more relevant risk than in non-diabetics. More versus less intensive blood pressure lowering or active versus placebo treatment can significantly prevent cardiovascular and renal events, with a particularly consistent reduction of proteinuria and microalbuminuria. Although several of the trials showing significant reduction of cardiovascular or renal risk achieved diastolic blood pressure (DBP) between 75 and 82 mmHg, systolic blood pressure (SBP) <140 mmHg was never achieved in trials showing cardiovascular benefits and SBP <130 mmHg was only achieved in two trials in normotensive subjects showing proteinuria reduction. The recommendation given by all major guidelines to lower SBP <130 mmHg appears to be difficult to comply with. Evidence of the superiority or inferiority of different drug classes (angiotensin-converting enzyme inhibitors, calcium antagonists, diuretics and beta-blockers) is rather vague, especially for cardiovascular protection. As to angiotensin-receptor antagonists, losartan has shown significant cardiovascular protection over a beta-blocker, and irbesartan, although not showing cardiovascular benefits over a calcium antagonist, was significantly better in retarding renal dysfunction and failure. Conclusions: In most trials on hypertensive diabetics, the large majority of patients were on two, three and even four-drug therapy. Therefore, it appears reasonable that all effective and well tolerated antihypertensive agents can be used in association to achieve DBP <80 mmHg and, whenever possible, SBP <130 or 135 mmHg, with the regular inclusion of an angiotensin-receptor antagonist for its proven renoprotective action. Hopefully, better guidance will be provided by further trials.

AB - Background: Patients with type-2 diabetes have a high prevalence of hypertension and show an elevated incidence of cardiovascular events and nephropathy. Objectives: Recent randomized trials of antihypertensive therapy providing information about cardiovascular and renal risk in diabetes, blood pressure goals and best suitable drugs were reviewed. Findings: Evidence that association of type-2 diabetes with hypertension markedly increases cardiovascular and renal risk is incontrovertible: even blood pressure values in the high-normal range represent a more relevant risk than in non-diabetics. More versus less intensive blood pressure lowering or active versus placebo treatment can significantly prevent cardiovascular and renal events, with a particularly consistent reduction of proteinuria and microalbuminuria. Although several of the trials showing significant reduction of cardiovascular or renal risk achieved diastolic blood pressure (DBP) between 75 and 82 mmHg, systolic blood pressure (SBP) <140 mmHg was never achieved in trials showing cardiovascular benefits and SBP <130 mmHg was only achieved in two trials in normotensive subjects showing proteinuria reduction. The recommendation given by all major guidelines to lower SBP <130 mmHg appears to be difficult to comply with. Evidence of the superiority or inferiority of different drug classes (angiotensin-converting enzyme inhibitors, calcium antagonists, diuretics and beta-blockers) is rather vague, especially for cardiovascular protection. As to angiotensin-receptor antagonists, losartan has shown significant cardiovascular protection over a beta-blocker, and irbesartan, although not showing cardiovascular benefits over a calcium antagonist, was significantly better in retarding renal dysfunction and failure. Conclusions: In most trials on hypertensive diabetics, the large majority of patients were on two, three and even four-drug therapy. Therefore, it appears reasonable that all effective and well tolerated antihypertensive agents can be used in association to achieve DBP <80 mmHg and, whenever possible, SBP <130 or 135 mmHg, with the regular inclusion of an angiotensin-receptor antagonist for its proven renoprotective action. Hopefully, better guidance will be provided by further trials.

KW - Antihypertensive therapy

KW - Cardiovascular events

KW - Diabetes mellitus

KW - Diabetic nephropathy

UR - http://www.scopus.com/inward/record.url?scp=0036854546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036854546&partnerID=8YFLogxK

U2 - 10.1097/00004872-200211000-00001

DO - 10.1097/00004872-200211000-00001

M3 - Article

C2 - 12409940

AN - SCOPUS:0036854546

VL - 20

SP - 2099

EP - 2110

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 11

ER -